Literature DB >> 33522960

Atypical HIV-vacuolar myelopathy: a case report.

Tau Mongezi1, Joseph Sibi2, George Jerry2, Ibañez-Valdés Lourdes de Fátima2, Dubula Tozama3, Foyaca Sibat Humberto4.   

Abstract

BACKGROUND: Here, we report an atypical HIV-vacuolar myelopathy and search the available medical literature about atypical presentations of human immunodeficiency virus associate vacuolar myelopathy (HIV-VM) and immunoglobulin therapy response. CASE: A 26-year-old lady who was 4 weeks postpartum presented to us with acute flaccid quadriparesis, with no sensory level. Extensive workup ruled out other causes of myelopathy. She developed a stage 3 acute kidney injury, and MRI showed diffuse cord atrophy involving the lower cervical and thoracic cord. The patient received IV-immunoglobulin, ARVs, and supportive therapy with inadequate response. Unfortunately, she developed nosocomial pneumonia and died. DISCUSSION: In HIV-VM, there is spinal cord atrophy, which mainly involves the thoracic cord. In our case, this pathological process also affected the spinal cord's cervical region, leading to flaccid tetraplegia, with high CD4 level, without response to the treatment, including intravenous immunoglobulin. KEYNOTES: Vacuolar myelopathy, HIV, Immunoglobulin therapy, flaccid tetraplegia, hypokalaemia. Renal failure.

Entities:  

Keywords:  Associated lesions of the nervous system; Case report; HIV-vacuolar myelopathy; Human immunodeficiency virus; Human immunodeficiency virus-associated myelopathy; Intravenous immunoglobulin administration

Mesh:

Year:  2021        PMID: 33522960      PMCID: PMC7851951          DOI: 10.1186/s40001-021-00483-0

Source DB:  PubMed          Journal:  Eur J Med Res        ISSN: 0949-2321            Impact factor:   2.175


  15 in total

1.  Remission of HIV myelopathy after highly active antiretroviral therapy.

Authors:  A Di Rocco; M Tagliati
Journal:  Neurology       Date:  2000-08-08       Impact factor: 9.910

2.  Pilot study of intravenous immunoglobulin in HIV-associated myelopathy.

Authors:  Katia Cikurel; Lauren Schiff; David M Simpson
Journal:  AIDS Patient Care STDS       Date:  2009-02       Impact factor: 5.078

3.  MR findings in AIDS-associated myelopathy.

Authors:  J Chong; A Di Rocco; M Tagliati; F Danisi; D M Simpson; S W Atlas
Journal:  AJNR Am J Neuroradiol       Date:  1999-09       Impact factor: 3.825

4.  Vacuolar myelopathy pathologically resembling subacute combined degeneration in patients with the acquired immunodeficiency syndrome.

Authors:  C K Petito; B A Navia; E S Cho; B D Jordan; D C George; R W Price
Journal:  N Engl J Med       Date:  1985-04-04       Impact factor: 91.245

5.  Guidelines for the diagnosis and management of neurological complications of HIV infection.

Authors:  P Portegies; L Solod; P Cinque; A Chaudhuri; J Begovac; I Everall; T Weber; M Bojar; P Martinez-Martin; P G E Kennedy
Journal:  Eur J Neurol       Date:  2004-05       Impact factor: 6.089

Review 6.  Unifying hypothesis for the pathogenesis of HIV-associated dementia complex, vacuolar myelopathy, and sensory neuropathy.

Authors:  W R Tyor; S L Wesselingh; J W Griffin; J C McArthur; D E Griffin
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1995-08-01

7.  Lower-extremity Dynamometry as a Novel Outcome Measure in a Double-blind, Placebo-controlled, Feasibility Trial of Intravenous Immunoglobulin (IVIG) for HIV-associated Myelopathy.

Authors:  Jessica Robinson-Papp; Mary Catherine George; Alexandra Nmashie; Donald Weisz; David M Simpson
Journal:  Innov Clin Neurosci       Date:  2018-02-01

8.  HIV-Associated Vacuolar Myelopathy and HIV-Associated Dementia as the Initial Manifestation of HIV/AIDS.

Authors:  Natalia Wuliji; Matthew J Mandell; Jason M Lunt; Adam Merando
Journal:  Case Rep Infect Dis       Date:  2019-09-15

9.  Approach to a case of myeloneuropathy.

Authors:  Ravindra Kumar Garg; Hardeep Singh Malhotra; Neeraj Kumar
Journal:  Ann Indian Acad Neurol       Date:  2016 Apr-Jun       Impact factor: 1.383

10.  Successful Treatment of Human Immunodeficiency Virus-Associated Highly Active Antiretroviral Therapy-Resistant Vacuolar Myelopathy with Intravenous Immunoglobulin.

Authors:  Lidiia N Prakhova; Aleksandr G Ilves; Svetlana N Kizhlo; Zhanna I Savintseva
Journal:  Ann Indian Acad Neurol       Date:  2020-02-25       Impact factor: 1.383

View more
  1 in total

1.  The utility of diffusion-weighted imaging in patients with spinal cord infarction: difference from the findings of neuromyelitis optica spectrum disorder.

Authors:  Makoto Kobayashi
Journal:  BMC Neurol       Date:  2022-10-11       Impact factor: 2.903

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.